肿瘤细胞治疗研究
英文原题：Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis.
本研究描绘了 CAR-T 细胞治疗在 GBM 中不断演变的科学图景，凸显了关键贡献者、机构合作以及新兴研究前沿。
背景：胶质母细胞瘤（GBM）是成人中侵袭性最强、致死率最高的原发性恶性脑肿瘤，具有高度异质性和显著免疫抑制性微环境。尽管手术、放疗和化疗不断进步，治疗结局仍然较差。嵌合抗原受体（CAR）T细胞疗法治疗血液系统恶性肿瘤疗效显著，目前正被探索用于GBM等实体瘤。鉴于相关研究迅速发展，亟需系统认识该领域的全球趋势和热点。方法：利用Web of Science核心合集，对建库至2024年12月31日有关CAR-T治疗GBM的论文开展全面文献计量和可视化分析。使用CiteSpace分析发表趋势、国家和机构合作、作者影响力、期刊共被引、参考文献网络及关键词共现、聚类和突现。结果：共纳入303篇相关论文。2015年起年发文量快速增长，美国和中国在论文产出及合作方面领先。Christine E. Brown和Donald M. O'Rourke等有影响力的作者被确定为核心贡献者。《Neuro-Oncology》和《Clinical Cancer Research》是重要发表及共被引期刊。共被引和关键词分析显示，研究重点已从早期的单抗原CAR设计（如IL13Rα2、EGFRvIII）转向双靶点构建体、“武装型”CAR-T及联合免疫疗法。近期热点包括免疫调节、精准医疗，以及纳米颗粒和溶瘤病毒等新型递送平台。结论：本研究描绘了CAR-T治疗GBM领域不断演变的科学图景，突出关键贡献者、机构合作和新兴研究前沿。从基础抗原靶向转向多功能、增强免疫的策略，反映出该领域日趋成熟并更加注重转化应用。研究结果可通过识别高影响力机构和作者，为资助战略提供参考；通过突出新兴联合及递送策略，优化临床试验设计；并通过分析共被引文献和关键词突现，指导新靶点发现。揭示全球合作网络和主题变化，也有助于推动GBM CAR-T治疗的跨学科研究框架发展。
BACKGROUND: Glioblastoma (GBM) is the most aggressive and lethal primary malignant brain tumor in adults, characterized by extensive heterogeneity and a profoundly immunosuppressive microenvironment. Despite advances in surgery, radiotherapy, and chemotherapy, therapeutic outcomes remain poor. Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable efficacy in hematologic malignancies and is now being explored for solid tumors such as GBM. Given the expanding research landscape, a systematic understanding of global trends and hotspots in this domain is urgently needed. METHODS: We conducted a comprehensive bibliometric and visualized analysis of publications related to CAR-T cell therapy in GBM from inception to December 31, 2024, using the Web of Science Core Collection. CiteSpace was used to analyze publication trends, country and institutional collaboration, author impact, journal co-citation, reference networks, and keyword co-occurrence, clustering, and bursts. RESULTS: A total of 303 relevant publications were included. Annual outputs showed rapid growth beginning in 2015, with the United States and China leading in productivity and collaboration. Influential authors such as Christine E. Brown and Donald M. O'Rourke were identified as core contributors. Neuro-Oncology and Clinical Cancer Research emerged as key publishing and co-cited journals. Co-citation and keyword analysis revealed a shift from early focus on single-antigen CAR designs (e.g., IL13R 2, EGFRvIII) toward dual-target constructs, "armored" CAR-T cells, and combinatorial immunotherapies. Recent research hotspots included immunomodulation, precision medicine, and novel delivery platforms such as nanoparticles and oncolytic viruses. CONCLUSIONS: This study maps the evolving scientific landscape of CAR-T cell therapy in GBM, highlighting key contributors, institutional collaboration, and emerging research frontiers. The transition from basic antigen targeting to multifunctional, immune-enhancing strategies reflects a maturing field with increasing translational focus. Our findings offer valuable insights that can inform strategic funding allocation by identifying high-impact institutions and authors, optimize clinical trial design by highlighting emerging combinatorial and delivery strategies, and guide novel target discovery through analysis of co-cited references and keyword bursts. By revealing global collaboration networks and thematic shifts, this study also supports the development of interdisciplinary research frameworks in CAR-T therapy for GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
